Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Clinical Study to Evaluate the Safety and Efficacy of Anti-CEA CAR-T Cells in the Treatment of Postoperative Minimal Residual Lesions in Colorectal Cancer Patients With Liver Metastases

ABSTRACT: Interventions: Single Group Dose Escalation Assignment:CAR-T cells infusion Primary outcome(s): Security (Incidence and severity of adverse events);Effectiveness (minimal residual disease);Efficacy (recurrence-free survival) Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 36953 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Towards minimal residual disease-directed therapy in melanoma

Project description:Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics, yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD we applied single-cell RNA-sequencing to malignant cells isolated from BRAF-mutant patient-derived xenograft (PDX) melanoma cohorts exposed to concurrent RAF/MEK-inhibition.

2018-07-18 | GSE116237 | GEO

Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia

Project description:GEP class prediction in association with CI-FISH (42 candidate genes) and patient MRD stratification Combined Interphase FISH (CI-FISH) for 42 candidate genes and Single Nucleotide Polymorphism (SNP) arrays were applied in a series of 51 T-ALL patients enrolled in Italy into the AIEOP-BFM ALL2000 protocol and stratified by Minimal Residual Disease (MRD). In 40 cases gene expression profiles (GEP) (Affymetrix HU-133 Plus 2.0 arrays) were available. This submission represents the gene expression component of the study

2013-11-05 | E-GEOD-39816 | biostudies-arrayexpress

Minimal Residual Disease in Mouse Hepatocellular carcinoma

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma

| PRJNA1014439 | ENA

Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases

Project description:Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence. Positive circulating tumor DNA (ctDNA) is the direct evidence of the minimal residual disease (MRD). In recent years, Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) has made great breakthroughs, and has achieved good therapeutic effects in hematological tumors, but the research on solid tumors is limited. CEA expression is generally elevated in gastrointestinal tumors and is associated with high aggressiveness of tumors. At present, solid tumor cell therapy targeting CEA has been carried out at home and abroad, and has achieved certain efficacy. Anti-CEA CAR-T cells targeting CEA have been constructed in the pre-clinical study of this project, and the pre-clinical study results suggest good safety and effectiveness. Formation of minimal residual disease is associated with circulating blood in the residual tumor cells. Using this feature, this project intends to conduct a phase I clinical study on patients with minimal residual disease /positive ctDNA after R0 resection of colorectal cancer liver metastasis, so as to conduct preliminary exploration of anti-CEA CAR-T cell therapy, evaluate the safety and effectiveness of the therapy, determine the maximum tolerated dose (MTD), and provide guidance for subsequent drug dosage and clinical trials.

| 2404766 | ecrin-mdr-crc

Towards minimal residual disease-directed therapy in melanoma

Project description:Towards minimal residual disease-directed therapy in melanoma

| PRJNA477841 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

| PRJNA1014440 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

| PRJNA1014444 | ENA

Metabolic memory underlying minimal residual disease in breast cancer

Project description:<p>Tumor relapse from treatment-resistant cells (minimal residual disease, MRD) underlies most breast cancer related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive. Here we integrated multi-omics data from a tractable organoid system with a metabolic modelling approach to uncover the metabolic and regulatory idiosyncrasies of the MRD. We find that the resistant cells, despite their non-proliferative phenotype and the absence of oncogenic signaling, feature increased glycolysis and activity of certain urea cycle enzymes reminiscent of the tumor. This metabolic distinctiveness was also evident in a mouse model and in transcriptomic data from patients following neo-adjuvant therapy. We further identified a marked similarity in DNA methylation profiles between tumor and residual cells. Taken together, our data reveal a metabolic and epigenetic memory of the treatment-resistant cells. We further demonstrate that the memorized elevated glycolysis in MRD is crucial for their survival and can be targeted using a small molecule inhibitor without impacting normal cells. The metabolic aberrances of MRD thus offer new therapeutic opportunities for post-treatment care to prevent breast tumor recurrence.</p>

2021-09-14 | MTBLS1507 | MetaboLights

Search for New Biomarkers for the Monitoring of the Minimal Residual Disease of the Acute Lymphoblastic Leukemia.

Project description:The main goal of the research was to find some new biomarkers for the monitoring of the Minimal Residual Disease in Acute Lymphoblastic Leukemia patients. Keywords: Search for new Biomarkers

2008-03-15 | GSE10820 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Residual tumor cells which remain dormant after MYC inactivation in a primary MYC-HCC derived cell line.

2024-08-06 | GSE242745 | GEO